Integra LifeSciences Stock Hits New 52-Week High (IART)

NEW YORK ( TheStreet) -- Integra LifeSciences Holdings (Nasdaq: IART) hit a new 52-week high Friday as it traded at $49.87 compared with its previous 52-Week high of $49.85. Integra LifeSciences is changing hands at $49.84 with 55,640 shares traded as of 10:51 a.m. ET. Average volume has been 138,200 shares over the past 30 days. Integra LifeSciences has a market cap of $1.4 billion and is part of the health care sector and health services industry. Shares are up 2.9% year to date as of the close of trading on Thursday.

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for neurosurgery, extremity reconstruction, orthopedics, and general surgery primarily in the United States, Europe, and the Asia Pacific. The company has a P/E ratio of 22.8, below the average health services industry P/E ratio of 23.3 and below the S&P 500 P/E ratio of 23.4.

TheStreet Ratings rates Integra LifeSciences as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, growth in earnings per share, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Integra LifeSciences Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Stocks Tumble as Trump Comments Lead to Worries Over China Trade Talks

Stocks Tumble as Trump Comments Lead to Worries Over China Trade Talks

Tiffany & Co. Sees a Strong Market in Asia

Tiffany & Co. Sees a Strong Market in Asia

Imagining the Stock Market in 10 Years

Imagining the Stock Market in 10 Years

Video: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Video: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Red Robin Slumps After Earnings Miss

Red Robin Slumps After Earnings Miss